JP2007531757A - 抗癌剤としての置換チオフェン誘導体 - Google Patents
抗癌剤としての置換チオフェン誘導体 Download PDFInfo
- Publication number
- JP2007531757A JP2007531757A JP2007506511A JP2007506511A JP2007531757A JP 2007531757 A JP2007531757 A JP 2007531757A JP 2007506511 A JP2007506511 A JP 2007506511A JP 2007506511 A JP2007506511 A JP 2007506511A JP 2007531757 A JP2007531757 A JP 2007531757A
- Authority
- JP
- Japan
- Prior art keywords
- carboxamide
- thiophene
- pyrimidin
- methylamino
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims description 8
- 150000003577 thiophenes Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 201
- 239000000203 mixture Substances 0.000 claims abstract description 157
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 45
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 claims abstract description 43
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 claims abstract description 43
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 230000001404 mediated effect Effects 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 239000000651 prodrug Substances 0.000 claims abstract description 10
- 229940002612 prodrug Drugs 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- -1 carboxyl ester Chemical class 0.000 claims description 588
- 125000000623 heterocyclic group Chemical group 0.000 claims description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims description 81
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 63
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 37
- 125000003107 substituted aryl group Chemical group 0.000 claims description 36
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 34
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 27
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 26
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000004104 aryloxy group Chemical group 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 14
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 12
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 125000004442 acylamino group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 10
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 10
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- VWEBSWBFMBFVOS-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-5-[5-methyl-2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=C(C)C(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=N1 VWEBSWBFMBFVOS-UHFFFAOYSA-N 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 5
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 150000003573 thiols Chemical class 0.000 claims description 5
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 claims description 3
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 claims description 3
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 3
- NBSAHLXYOZVQLE-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-sulfonamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)S(=O)(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 NBSAHLXYOZVQLE-UHFFFAOYSA-N 0.000 claims description 3
- JJYPEEFKRBLOSR-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC=C1C1=CC=NC(N)=N1 JJYPEEFKRBLOSR-UHFFFAOYSA-N 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- QPYFGRWLGVZTGI-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-sulfonamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 QPYFGRWLGVZTGI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 2
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims description 2
- 125000006188 2-phenyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- XPQRYCUXLRXKMQ-UHFFFAOYSA-N 3-amino-n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=C(N)C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 XPQRYCUXLRXKMQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- IHXNIOYEXQWUNI-UHFFFAOYSA-N 4,5-dihydro-1h-pyrimidin-6-one Chemical compound O=C1CCN=CN1 IHXNIOYEXQWUNI-UHFFFAOYSA-N 0.000 claims description 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- LIGYTORWTOTIQC-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-phenylethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC=CC=2)=N1 LIGYTORWTOTIQC-UHFFFAOYSA-N 0.000 claims description 2
- SSVSNUYEDRPXJR-UHFFFAOYSA-N 6-(2-aminopyrimidin-4-yl)-3-[2-(2,4-dichlorophenyl)ethyl]thieno[3,2-d]pyrimidin-4-one Chemical compound NC1=NC=CC(C=2SC=3C(=O)N(CCC=4C(=CC(Cl)=CC=4)Cl)C=NC=3C=2)=N1 SSVSNUYEDRPXJR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 125000000638 benzylaminocarbonyl group Chemical group C(C1=CC=CC=C1)NC(=O)* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 2
- UQJIBVBUYFZGLL-UHFFFAOYSA-N n-(4-chloro-1,3-benzothiazol-2-yl)-3-hydroxy-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=C(O)C=2)C(=O)NC=2SC3=CC=CC(Cl)=C3N=2)=N1 UQJIBVBUYFZGLL-UHFFFAOYSA-N 0.000 claims description 2
- AEFXFKAEVKAHGS-UHFFFAOYSA-N n-(4-methoxy-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(OC)=C3N=2)=N1 AEFXFKAEVKAHGS-UHFFFAOYSA-N 0.000 claims description 2
- HIJOLKIVKMBZSX-HNNXBMFYSA-N n-[(2s)-1-amino-3-(2,4-dichlorophenyl)propan-2-yl]-5-pyridin-4-ylthiophene-2-carboxamide Chemical compound C([C@@H](CN)NC(=O)C=1SC(=CC=1)C=1C=CN=CC=1)C1=CC=C(Cl)C=C1Cl HIJOLKIVKMBZSX-HNNXBMFYSA-N 0.000 claims description 2
- XURUQPNEBSLOTC-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-5-[2-(methylamino)pyridin-4-yl]thiophene-2-carboxamide Chemical compound C1=NC(NC)=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=C1 XURUQPNEBSLOTC-UHFFFAOYSA-N 0.000 claims description 2
- VQWCRDHPNXZMIT-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=N1 VQWCRDHPNXZMIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 3
- WEXAVDOGLDFHQL-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-methoxy-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound N=1C=2C(OC)=CC=CC=2SC=1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 WEXAVDOGLDFHQL-UHFFFAOYSA-N 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- HHOVRZGUSBMKKU-ZDUSSCGKSA-N n-[(1s)-2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)N[C@H](CN)CC=2C(=CC(Cl)=CC=2)Cl)=N1 HHOVRZGUSBMKKU-ZDUSSCGKSA-N 0.000 claims 2
- 125000000980 1H-indol-3-ylmethyl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[*])C2=C1[H] 0.000 claims 1
- MZWHUYLRDIDNRG-UHFFFAOYSA-N 3-(2-aminoethoxy)-n-(4-chloro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=C(OCCN)C=2)C(=O)NC=2SC3=CC=CC(Cl)=C3N=2)=N1 MZWHUYLRDIDNRG-UHFFFAOYSA-N 0.000 claims 1
- BPRGBSYSQVRXNR-UHFFFAOYSA-N 3-[2-(2,4-dichlorophenyl)ethyl]-6-[2-(methylamino)pyrimidin-4-yl]thieno[3,2-d]pyrimidin-4-one Chemical compound CNC1=NC=CC(C=2SC=3C(=O)N(CCC=4C(=CC(Cl)=CC=4)Cl)C=NC=3C=2)=N1 BPRGBSYSQVRXNR-UHFFFAOYSA-N 0.000 claims 1
- QNVHMIQCVOXFHS-UHFFFAOYSA-N 3-amino-n-(4-chloro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=C(N)C=2)C(=O)NC=2SC3=CC=CC(Cl)=C3N=2)=N1 QNVHMIQCVOXFHS-UHFFFAOYSA-N 0.000 claims 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- HWOYVCYUWKJONH-UHFFFAOYSA-N 4-chloro-n-[[5-[2-(methylamino)pyrimidin-4-yl]thiophen-2-yl]methyl]-1,3-benzothiazol-2-amine Chemical compound CNC1=NC=CC(C=2SC(CNC=3SC4=CC=CC(Cl)=C4N=3)=CC=2)=N1 HWOYVCYUWKJONH-UHFFFAOYSA-N 0.000 claims 1
- NPTZTUDTQQZJDC-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC=C3N=2)=N1 NPTZTUDTQQZJDC-UHFFFAOYSA-N 0.000 claims 1
- FNEVLTPNUHMCJW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(1h-benzimidazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2NC3=CC=CC=C3N=2)=N1 FNEVLTPNUHMCJW-UHFFFAOYSA-N 0.000 claims 1
- PYYUPKMXPCFNBT-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(2-hydroxy-1-phenylethyl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC(CO)C=2C=CC=CC=2)=N1 PYYUPKMXPCFNBT-UHFFFAOYSA-N 0.000 claims 1
- XMEWJNGGFIDRIO-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(2-phenylpropyl)thiophene-2-carboxamide Chemical compound C=1C=CC=CC=1C(C)CNC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 XMEWJNGGFIDRIO-UHFFFAOYSA-N 0.000 claims 1
- XNANVNNMNLUYPZ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(2-pyridin-3-ylethyl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=NC=CC=2)=N1 XNANVNNMNLUYPZ-UHFFFAOYSA-N 0.000 claims 1
- CRBQBIVQWYSTAN-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4,6-dichloro-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(Cl)=CC(Cl)=C3N=2)=N1 CRBQBIVQWYSTAN-UHFFFAOYSA-N 0.000 claims 1
- MTKKCZSXSDQIAQ-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4,6-difluoro-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(F)=CC(F)=C3N=2)=N1 MTKKCZSXSDQIAQ-UHFFFAOYSA-N 0.000 claims 1
- HUBYTTGYYAONET-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-bromo-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(Br)=C3N=2)=N1 HUBYTTGYYAONET-UHFFFAOYSA-N 0.000 claims 1
- XMGDTDAXGWPTSR-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-chloro-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(Cl)=C3N=2)=N1 XMGDTDAXGWPTSR-UHFFFAOYSA-N 0.000 claims 1
- JFHNDLNJWMSSJU-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-chloro-1,3-benzoxazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2OC3=CC=CC(Cl)=C3N=2)=N1 JFHNDLNJWMSSJU-UHFFFAOYSA-N 0.000 claims 1
- QXRYEJPCGMQPGU-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-chloro-6-methyl-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(C)=CC(Cl)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 QXRYEJPCGMQPGU-UHFFFAOYSA-N 0.000 claims 1
- NQNWPDHBHJBOQN-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-fluoro-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(F)=C3N=2)=N1 NQNWPDHBHJBOQN-UHFFFAOYSA-N 0.000 claims 1
- AUKWTEYRSILVGT-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-hydroxy-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(O)=C3N=2)=N1 AUKWTEYRSILVGT-UHFFFAOYSA-N 0.000 claims 1
- SUJCLYSOQYHCER-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-phenyl-1,3-thiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=CC=CC=2)=N1 SUJCLYSOQYHCER-UHFFFAOYSA-N 0.000 claims 1
- UHAYTDSERFCPIU-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2N=CC=CC=2)=N1 UHAYTDSERFCPIU-UHFFFAOYSA-N 0.000 claims 1
- QOKWBHQYKMVXLN-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(4-pyridin-3-yl-1,3-thiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=NC=CC=2)=N1 QOKWBHQYKMVXLN-UHFFFAOYSA-N 0.000 claims 1
- LAHORGMYKLZDPA-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(5-chloro-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=C(Cl)C=C3N=2)=N1 LAHORGMYKLZDPA-UHFFFAOYSA-N 0.000 claims 1
- KVEMIEMSWHDUIY-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-(7-chloro-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=C(Cl)C=CC=C3N=2)=N1 KVEMIEMSWHDUIY-UHFFFAOYSA-N 0.000 claims 1
- KGICFSCMVZEXTP-ZDUSSCGKSA-N 5-(2-aminopyrimidin-4-yl)-n-[(2r)-2-(4-chlorophenyl)-2-hydroxyethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC[C@H](O)C=2C=CC(Cl)=CC=2)=N1 KGICFSCMVZEXTP-ZDUSSCGKSA-N 0.000 claims 1
- XMEWJNGGFIDRIO-LBPRGKRZSA-N 5-(2-aminopyrimidin-4-yl)-n-[(2r)-2-phenylpropyl]thiophene-2-carboxamide Chemical compound C([C@H](C)C=1C=CC=CC=1)NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 XMEWJNGGFIDRIO-LBPRGKRZSA-N 0.000 claims 1
- XMEWJNGGFIDRIO-GFCCVEGCSA-N 5-(2-aminopyrimidin-4-yl)-n-[(2s)-2-phenylpropyl]thiophene-2-carboxamide Chemical compound C([C@@H](C)C=1C=CC=CC=1)NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 XMEWJNGGFIDRIO-GFCCVEGCSA-N 0.000 claims 1
- CFLCOFVWOJTRCB-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]thiophene-2-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C(CCN(C)C)NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 CFLCOFVWOJTRCB-UHFFFAOYSA-N 0.000 claims 1
- UZJHGGDNLWLNIC-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 UZJHGGDNLWLNIC-UHFFFAOYSA-N 0.000 claims 1
- MAXALQSSMNJURH-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,4-dichlorophenyl)pent-4-enyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(CC=C)C=2C(=CC(Cl)=CC=2)Cl)=N1 MAXALQSSMNJURH-UHFFFAOYSA-N 0.000 claims 1
- SPMCOJWMYNBROI-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,4-dichlorophenyl)pent-4-ynyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(CC#C)C=2C(=CC(Cl)=CC=2)Cl)=N1 SPMCOJWMYNBROI-UHFFFAOYSA-N 0.000 claims 1
- YHSMOAXQCDDYTD-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,4-dichlorophenyl)pentyl]thiophene-2-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CNC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 YHSMOAXQCDDYTD-UHFFFAOYSA-N 0.000 claims 1
- RCIHDNFMDYSGRD-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,4-dichlorophenyl)propyl]thiophene-2-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(C)CNC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 RCIHDNFMDYSGRD-UHFFFAOYSA-N 0.000 claims 1
- LPVFDFUNENYSFU-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2,6-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=CC=2Cl)Cl)=N1 LPVFDFUNENYSFU-UHFFFAOYSA-N 0.000 claims 1
- PEDRXWZBJBNIOW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2-chlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=CC=2)Cl)=N1 PEDRXWZBJBNIOW-UHFFFAOYSA-N 0.000 claims 1
- LANAZOCDBPOFPX-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2-fluoro-4-methoxyphenyl)ethyl]thiophene-2-carboxamide Chemical compound FC1=CC(OC)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(N)N=CC=2)S1 LANAZOCDBPOFPX-UHFFFAOYSA-N 0.000 claims 1
- SQVVLPCNHZIYMB-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(2-fluoro-4-methylphenyl)ethyl]thiophene-2-carboxamide Chemical compound FC1=CC(C)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(N)N=CC=2)S1 SQVVLPCNHZIYMB-UHFFFAOYSA-N 0.000 claims 1
- NUTJLMPCFZERPW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(3,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(Cl)C(Cl)=CC=2)=N1 NUTJLMPCFZERPW-UHFFFAOYSA-N 0.000 claims 1
- AWDIZMAZPSUOPG-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(3-chlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(Cl)C=CC=2)=N1 AWDIZMAZPSUOPG-UHFFFAOYSA-N 0.000 claims 1
- XKBGGFLQRNZRJW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(4-chlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(Cl)=CC=2)=N1 XKBGGFLQRNZRJW-UHFFFAOYSA-N 0.000 claims 1
- NTYZKDOMUPHNRB-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(4-fluorophenyl)ethyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=N1 NTYZKDOMUPHNRB-UHFFFAOYSA-N 0.000 claims 1
- RNADBBOCLFKEFW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[2-(4-fluorophenyl)ethyl]thiophene-2-sulfonamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)S(=O)(=O)NCCC=2C=CC(F)=CC=2)=N1 RNADBBOCLFKEFW-UHFFFAOYSA-N 0.000 claims 1
- JPEZMMIWJRFRFN-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C(=CC=CC=2)Cl)=N1 JPEZMMIWJRFRFN-UHFFFAOYSA-N 0.000 claims 1
- DTDCBIKDTZKDRC-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=C(F)C(F)=CC=2)=N1 DTDCBIKDTZKDRC-UHFFFAOYSA-N 0.000 claims 1
- UWZFVXSUYUSLJH-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-(3-chlorophenyl)-1,3-thiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=C(Cl)C=CC=2)=N1 UWZFVXSUYUSLJH-UHFFFAOYSA-N 0.000 claims 1
- BGFTVXXILCFFDY-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]thiophene-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CSC(NC(=O)C=2SC(=CC=2)C=2N=C(N)N=CC=2)=N1 BGFTVXXILCFFDY-UHFFFAOYSA-N 0.000 claims 1
- FDBIYDXSNVVOKR-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-chloro-6-(2-nitroethyl)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CC[N+]([O-])=O)=CC(Cl)=C3N=2)=N1 FDBIYDXSNVVOKR-UHFFFAOYSA-N 0.000 claims 1
- ODNWBUAWVNJCIX-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-chloro-6-(hydroxymethyl)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CO)=CC(Cl)=C3N=2)=N1 ODNWBUAWVNJCIX-UHFFFAOYSA-N 0.000 claims 1
- QXDRCBXIBWLXER-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-chloro-6-(morpholin-4-ylmethyl)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN4CCOCC4)=CC(Cl)=C3N=2)=N1 QXDRCBXIBWLXER-UHFFFAOYSA-N 0.000 claims 1
- GKWAVOOYICWTIK-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-chloro-6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(OC(F)(F)F)=CC(Cl)=C3N=2)=N1 GKWAVOOYICWTIK-UHFFFAOYSA-N 0.000 claims 1
- BXSQEDMSIROAAW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-chloro-6-(trifluoromethyl)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(=CC(Cl)=C3N=2)C(F)(F)F)=N1 BXSQEDMSIROAAW-UHFFFAOYSA-N 0.000 claims 1
- VEJCRRQADBUYFT-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[4-chloro-6-[(dimethylamino)methyl]-1,3-benzothiazol-2-yl]thiophene-2-carboxamide Chemical compound S1C2=CC(CN(C)C)=CC(Cl)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 VEJCRRQADBUYFT-UHFFFAOYSA-N 0.000 claims 1
- ACNGIGBNSAVXLG-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[5-(3-bromo-4-methoxyphenyl)-1,3-thiazol-2-yl]thiophene-2-carboxamide Chemical compound C1=C(Br)C(OC)=CC=C1C(S1)=CN=C1NC(=O)C1=CC=C(C=2N=C(N)N=CC=2)S1 ACNGIGBNSAVXLG-UHFFFAOYSA-N 0.000 claims 1
- FDKNPSYDZBINEL-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[[1-(4-chlorophenyl)cyclobutyl]methyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCC2(CCC2)C=2C=CC(Cl)=CC=2)=N1 FDKNPSYDZBINEL-UHFFFAOYSA-N 0.000 claims 1
- CMRWNLCSJWAETG-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-n-[[1-(4-chlorophenyl)cyclopropyl]methyl]thiophene-2-carboxamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)C(=O)NCC2(CC2)C=2C=CC(Cl)=CC=2)=N1 CMRWNLCSJWAETG-UHFFFAOYSA-N 0.000 claims 1
- NVNZUMSKDWXVBS-UHFFFAOYSA-N 5-(2-anilinopyrimidin-4-yl)-n-[2-(4-fluorophenyl)ethyl]thiophene-2-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC=3C=CC=CC=3)N=CC=2)S1 NVNZUMSKDWXVBS-UHFFFAOYSA-N 0.000 claims 1
- UAXGDOWTVZTQBY-UHFFFAOYSA-N 5-[2-(benzylamino)pyrimidin-4-yl]-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NCC=3C=CC=CC=3)N=CC=2)S1 UAXGDOWTVZTQBY-UHFFFAOYSA-N 0.000 claims 1
- FMXKEISBOAKKPN-UHFFFAOYSA-N 5-[2-(butylamino)pyrimidin-4-yl]-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound CCCCNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 FMXKEISBOAKKPN-UHFFFAOYSA-N 0.000 claims 1
- FYBVWFQTQKULGT-UHFFFAOYSA-N 5-[2-(cyclobutylamino)pyrimidin-4-yl]-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC3CCC3)N=CC=2)S1 FYBVWFQTQKULGT-UHFFFAOYSA-N 0.000 claims 1
- WQULOHAJMAQTLC-UHFFFAOYSA-N 5-[2-(cyclopentylamino)pyrimidin-4-yl]-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC3CCCC3)N=CC=2)S1 WQULOHAJMAQTLC-UHFFFAOYSA-N 0.000 claims 1
- XWBHEAVRYIOCDA-UHFFFAOYSA-N 5-[2-(cyclopropylamino)pyrimidin-4-yl]-n-[2-(2,4-dichlorophenyl)ethyl]thiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC3CC3)N=CC=2)S1 XWBHEAVRYIOCDA-UHFFFAOYSA-N 0.000 claims 1
- AGZCRDGUZJDKNH-UHFFFAOYSA-N 5-[2-(dimethylamino)pyrimidin-4-yl]-n-[2-(4-fluorophenyl)ethyl]thiophene-2-carboxamide Chemical compound CN(C)C1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=N1 AGZCRDGUZJDKNH-UHFFFAOYSA-N 0.000 claims 1
- RDSOQXDTFGIAGL-UHFFFAOYSA-N 5-[2-(ethylamino)pyrimidin-4-yl]-n-[2-(4-fluorophenyl)ethyl]thiophene-2-carboxamide Chemical compound CCNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=N1 RDSOQXDTFGIAGL-UHFFFAOYSA-N 0.000 claims 1
- YAQZTVOEXWBHGW-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(1,2,3,4-tetrahydronaphthalen-1-yl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC2C3=CC=CC=C3CCC2)=N1 YAQZTVOEXWBHGW-UHFFFAOYSA-N 0.000 claims 1
- MLCRRFSSEJCWKM-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-morpholin-4-yl-2-phenylethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(N2CCOCC2)C=2C=CC=CC=2)=N1 MLCRRFSSEJCWKM-UHFFFAOYSA-N 0.000 claims 1
- YVWCLQZBYNEBCS-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-morpholin-4-ylethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCN2CCOCC2)=N1 YVWCLQZBYNEBCS-UHFFFAOYSA-N 0.000 claims 1
- FSBMMNCTVJSKAQ-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-phenylpropyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(C)C=2C=CC=CC=2)=N1 FSBMMNCTVJSKAQ-UHFFFAOYSA-N 0.000 claims 1
- INKVUIMEZCZJDU-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-piperidin-1-ylethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCN2CCCCC2)=N1 INKVUIMEZCZJDU-UHFFFAOYSA-N 0.000 claims 1
- ANCMTSBLWZPSQD-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-pyridin-2-ylethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2N=CC=CC=2)=N1 ANCMTSBLWZPSQD-UHFFFAOYSA-N 0.000 claims 1
- MZGSYIGYCQFSKV-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(2-pyridin-4-ylethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CN=CC=2)=N1 MZGSYIGYCQFSKV-UHFFFAOYSA-N 0.000 claims 1
- AUJSQMWSRIQLKJ-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(4-methyl-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(C)=C3N=2)=N1 AUJSQMWSRIQLKJ-UHFFFAOYSA-N 0.000 claims 1
- FMHNLORGXCTUBC-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(4-phenyl-1,3-thiazol-2-yl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=CC=CC=2)=N1 FMHNLORGXCTUBC-UHFFFAOYSA-N 0.000 claims 1
- ILOADZQIXIGSNS-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2N=CC=CC=2)=N1 ILOADZQIXIGSNS-UHFFFAOYSA-N 0.000 claims 1
- BMSMVHRXCQBORR-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(4-pyridin-3-yl-1,3-thiazol-2-yl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=NC=CC=2)=N1 BMSMVHRXCQBORR-UHFFFAOYSA-N 0.000 claims 1
- OFXUEAVLIYUDNI-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(pyridin-2-ylmethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC=2N=CC=CC=2)=N1 OFXUEAVLIYUDNI-UHFFFAOYSA-N 0.000 claims 1
- VGWYYDFAUBZGTJ-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(pyridin-3-ylmethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC=2C=NC=CC=2)=N1 VGWYYDFAUBZGTJ-UHFFFAOYSA-N 0.000 claims 1
- LXVDFAWPGBSWCR-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-(pyridin-4-ylmethyl)thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC=2C=CN=CC=2)=N1 LXVDFAWPGBSWCR-UHFFFAOYSA-N 0.000 claims 1
- FSBMMNCTVJSKAQ-ZDUSSCGKSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-[(2r)-2-phenylpropyl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC[C@H](C)C=2C=CC=CC=2)=N1 FSBMMNCTVJSKAQ-ZDUSSCGKSA-N 0.000 claims 1
- FSBMMNCTVJSKAQ-CYBMUJFWSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-[(2s)-2-phenylpropyl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC[C@@H](C)C=2C=CC=CC=2)=N1 FSBMMNCTVJSKAQ-CYBMUJFWSA-N 0.000 claims 1
- KWWNNIKIVXQIJU-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-[2-(4-methylphenyl)ethyl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(C)=CC=2)=N1 KWWNNIKIVXQIJU-UHFFFAOYSA-N 0.000 claims 1
- AOYOYTUZOHDUMY-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-[2-(4-methylpiperazin-1-yl)ethyl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCN2CCN(C)CC2)=N1 AOYOYTUZOHDUMY-UHFFFAOYSA-N 0.000 claims 1
- AOCZJDPDLIJLCR-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-[2-(4-phenoxyphenyl)ethyl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 AOCZJDPDLIJLCR-UHFFFAOYSA-N 0.000 claims 1
- SQLQMQPHQGTPHS-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-piperidin-3-ylthiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC2CNCCC2)=N1 SQLQMQPHQGTPHS-UHFFFAOYSA-N 0.000 claims 1
- BFVNGLYYIBSCFZ-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-pyrrolidin-3-ylthiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC2CNCC2)=N1 BFVNGLYYIBSCFZ-UHFFFAOYSA-N 0.000 claims 1
- AKFSTAXJYQVCLG-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-quinolin-2-ylthiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2N=C3C=CC=CC3=CC=2)=N1 AKFSTAXJYQVCLG-UHFFFAOYSA-N 0.000 claims 1
- WSVGIONTZPMOKG-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-quinolin-3-ylthiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2C=C3C=CC=CC3=NC=2)=N1 WSVGIONTZPMOKG-UHFFFAOYSA-N 0.000 claims 1
- FQUGBOHRQSPEBF-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]-n-quinolin-6-ylthiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2C=C3C=CC=NC3=CC=2)=N1 FQUGBOHRQSPEBF-UHFFFAOYSA-N 0.000 claims 1
- XZWFFMMANAOYPA-UHFFFAOYSA-N 5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(N)=O)=N1 XZWFFMMANAOYPA-UHFFFAOYSA-N 0.000 claims 1
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 claims 1
- 125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- RTPVYTSJFKBAOC-UHFFFAOYSA-N methyl 2-[[5-(2-aminopyrimidin-4-yl)thiophene-2-carbonyl]amino]-4-chloro-1,3-benzothiazole-5-carboxylate Chemical compound N=1C2=C(Cl)C(C(=O)OC)=CC=C2SC=1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 RTPVYTSJFKBAOC-UHFFFAOYSA-N 0.000 claims 1
- YOGAYYYZPISLTN-UHFFFAOYSA-N methyl 4-chloro-2-[[5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carbonyl]amino]-1,3-benzothiazole-5-carboxylate Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=C(C(Cl)=C3N=2)C(=O)OC)=N1 YOGAYYYZPISLTN-UHFFFAOYSA-N 0.000 claims 1
- GFUONLMQSGRDEX-UHFFFAOYSA-N n-(1,2-diphenylethyl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC(CC=2C=CC=CC=2)C=2C=CC=CC=2)=N1 GFUONLMQSGRDEX-UHFFFAOYSA-N 0.000 claims 1
- UVIDDQVRCBLANS-UHFFFAOYSA-N n-(1-benzylpyrrolidin-3-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC2CN(CC=3C=CC=CC=3)CC2)=N1 UVIDDQVRCBLANS-UHFFFAOYSA-N 0.000 claims 1
- NJHYYLPVLKEBQP-UHFFFAOYSA-N n-(2,2-diphenylethyl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 NJHYYLPVLKEBQP-UHFFFAOYSA-N 0.000 claims 1
- GTZNGZIDDWCVEG-UHFFFAOYSA-N n-(2-aminoethyl)-4-chloro-2-[[5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carbonyl]amino]-1,3-benzothiazole-6-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(=CC(Cl)=C3N=2)C(=O)NCCN)=N1 GTZNGZIDDWCVEG-UHFFFAOYSA-N 0.000 claims 1
- BMCNSGBPGWNGAW-UHFFFAOYSA-N n-(2-aminoethyl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCN)=N1 BMCNSGBPGWNGAW-UHFFFAOYSA-N 0.000 claims 1
- YQIFHDIODVEVBD-UHFFFAOYSA-N n-(2-aminoethyl)-n-(4-chloro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)N(CCN)C=2SC3=CC=CC(Cl)=C3N=2)=N1 YQIFHDIODVEVBD-UHFFFAOYSA-N 0.000 claims 1
- FYRLHDAYSIJVQN-UHFFFAOYSA-N n-(4,6-difluoro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(F)=CC(F)=C3N=2)=N1 FYRLHDAYSIJVQN-UHFFFAOYSA-N 0.000 claims 1
- VOMRJFKDDQGCSZ-UHFFFAOYSA-N n-(4-chloro-1,3-benzothiazol-2-yl)-3-methoxy-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=C(OC)C=2)C(=O)NC=2SC3=CC=CC(Cl)=C3N=2)=N1 VOMRJFKDDQGCSZ-UHFFFAOYSA-N 0.000 claims 1
- UBXMUHDEMWWYEP-UHFFFAOYSA-N n-(4-chloro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(Cl)=C3N=2)=N1 UBXMUHDEMWWYEP-UHFFFAOYSA-N 0.000 claims 1
- TYBUDXLJBAFHPA-UHFFFAOYSA-N n-(4-chloro-1,3-benzothiazol-2-yl)-n-methyl-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)N(C)C=2SC3=CC=CC(Cl)=C3N=2)=N1 TYBUDXLJBAFHPA-UHFFFAOYSA-N 0.000 claims 1
- IOVATEWBWZGHIZ-UHFFFAOYSA-N n-(4-chloro-1,3-benzoxazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2OC3=CC=CC(Cl)=C3N=2)=N1 IOVATEWBWZGHIZ-UHFFFAOYSA-N 0.000 claims 1
- SLSKJTKRUUWBKY-UHFFFAOYSA-N n-(4-chloro-6-methyl-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(C)=CC(Cl)=C3N=2)=N1 SLSKJTKRUUWBKY-UHFFFAOYSA-N 0.000 claims 1
- SLGMKFVHOSMRMA-UHFFFAOYSA-N n-(4-fluorophenyl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2C=CC(F)=CC=2)=N1 SLGMKFVHOSMRMA-UHFFFAOYSA-N 0.000 claims 1
- JTCNQIBIJBDQCP-UHFFFAOYSA-N n-(4-hydroxy-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(O)=C3N=2)=N1 JTCNQIBIJBDQCP-UHFFFAOYSA-N 0.000 claims 1
- UNQPSFNJYHZYEX-UHFFFAOYSA-N n-(5-chloro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=C(Cl)C=C3N=2)=N1 UNQPSFNJYHZYEX-UHFFFAOYSA-N 0.000 claims 1
- QVKDBDYFPRZLLB-UHFFFAOYSA-N n-(6-fluoro-1,3-benzothiazol-2-yl)-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(F)=CC=C3N=2)=N1 QVKDBDYFPRZLLB-UHFFFAOYSA-N 0.000 claims 1
- TVBATRHELCPWFC-XPCCGILXSA-N n-[(2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC2C3=CC=CC=C3C[C@H]2O)=N1 TVBATRHELCPWFC-XPCCGILXSA-N 0.000 claims 1
- SLIFUDFEWWHQQI-GFCCVEGCSA-N n-[(2s)-2-amino-2-phenylethyl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound C([C@@H](N)C=1C=CC=CC=1)NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 SLIFUDFEWWHQQI-GFCCVEGCSA-N 0.000 claims 1
- XPMIPHQPUWQWIB-CYBMUJFWSA-N n-[(2s)-2-amino-2-phenylethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC[C@@H](N)C=2C=CC=CC=2)=N1 XPMIPHQPUWQWIB-CYBMUJFWSA-N 0.000 claims 1
- SFSMICBLCBGDLK-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC=2C=CC(F)=CC=2)=N1 SFSMICBLCBGDLK-UHFFFAOYSA-N 0.000 claims 1
- UOLYTRAUGYBDOZ-UHFFFAOYSA-N n-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC(CCN(C)C)C=2C=CC(Cl)=CC=2)=N1 UOLYTRAUGYBDOZ-UHFFFAOYSA-N 0.000 claims 1
- HTKHGJMBTREOOL-UHFFFAOYSA-N n-[1-(4-chlorophenyl)-3-hydroxypropyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC(CCO)C=2C=CC(Cl)=CC=2)=N1 HTKHGJMBTREOOL-UHFFFAOYSA-N 0.000 claims 1
- YZNHMSYFPSNFCI-UHFFFAOYSA-N n-[1-(4-fluorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC(C)C=2C=CC(F)=CC=2)=N1 YZNHMSYFPSNFCI-UHFFFAOYSA-N 0.000 claims 1
- MXMKADGJEUXBFS-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(dimethylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CN(C)C1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 MXMKADGJEUXBFS-UHFFFAOYSA-N 0.000 claims 1
- VFIZNSNMLQIIMY-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(ethylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CCNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 VFIZNSNMLQIIMY-UHFFFAOYSA-N 0.000 claims 1
- SMYXXLZMXSZYRT-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(methylamino)pyridin-4-yl]thiophene-2-carboxamide Chemical compound C1=NC(NC)=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=C1 SMYXXLZMXSZYRT-UHFFFAOYSA-N 0.000 claims 1
- MPABKDRFTWVLMC-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 MPABKDRFTWVLMC-UHFFFAOYSA-N 0.000 claims 1
- ZMPQDHMDRQYSKY-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-sulfonamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)S(=O)(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 ZMPQDHMDRQYSKY-UHFFFAOYSA-N 0.000 claims 1
- HYOWGDCBCIXWAP-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(propylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CCCNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 HYOWGDCBCIXWAP-UHFFFAOYSA-N 0.000 claims 1
- DYESAQIRADGESU-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(pyridin-4-ylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC=3C=CN=CC=3)N=CC=2)S1 DYESAQIRADGESU-UHFFFAOYSA-N 0.000 claims 1
- MMQXDJGZVCZRSJ-YDNXMHBPSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-[[(2s)-2-phenylcyclopropyl]amino]pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC3[C@@H](C3)C=3C=CC=CC=3)N=CC=2)S1 MMQXDJGZVCZRSJ-YDNXMHBPSA-N 0.000 claims 1
- VLICBHXEYNKDHC-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[4-(methylamino)-1,3,5-triazin-2-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=NC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 VLICBHXEYNKDHC-UHFFFAOYSA-N 0.000 claims 1
- PYVYBANUWNFBKC-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-pyrimidin-4-ylthiophene-2-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1=CC=C(C=2N=CN=CC=2)S1 PYVYBANUWNFBKC-UHFFFAOYSA-N 0.000 claims 1
- LVGSFJIMINBHKE-UHFFFAOYSA-N n-[2-(2,5-dimethoxyphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=C(OC)C=2)OC)=N1 LVGSFJIMINBHKE-UHFFFAOYSA-N 0.000 claims 1
- QMGOSDFBFDADFB-UHFFFAOYSA-N n-[2-(2,6-dichlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=CC=2Cl)Cl)=N1 QMGOSDFBFDADFB-UHFFFAOYSA-N 0.000 claims 1
- UCRVNWSQOAMWMH-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=CC=2)Cl)=N1 UCRVNWSQOAMWMH-UHFFFAOYSA-N 0.000 claims 1
- FHDAWHASPNWEPU-UHFFFAOYSA-N n-[2-(2-fluorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=CC=2)F)=N1 FHDAWHASPNWEPU-UHFFFAOYSA-N 0.000 claims 1
- CTHWZLWFDWJTKZ-UHFFFAOYSA-N n-[2-(2-methoxyphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C(=CC=CC=2)OC)=N1 CTHWZLWFDWJTKZ-UHFFFAOYSA-N 0.000 claims 1
- QLGHBSUHBXDGLW-UHFFFAOYSA-N n-[2-(3,4-dichlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(Cl)C(Cl)=CC=2)=N1 QLGHBSUHBXDGLW-UHFFFAOYSA-N 0.000 claims 1
- URWRQQWYHAMDAH-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(OC)C(OC)=CC=2)=N1 URWRQQWYHAMDAH-UHFFFAOYSA-N 0.000 claims 1
- YRCTVYMPNWIFAJ-UHFFFAOYSA-N n-[2-(3-chlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(Cl)C=CC=2)=N1 YRCTVYMPNWIFAJ-UHFFFAOYSA-N 0.000 claims 1
- ICKXYJSTJUCBBZ-UHFFFAOYSA-N n-[2-(3-fluorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(F)C=CC=2)=N1 ICKXYJSTJUCBBZ-UHFFFAOYSA-N 0.000 claims 1
- PVEICDOYZVUTLN-UHFFFAOYSA-N n-[2-(3-methoxyphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=C(OC)C=CC=2)=N1 PVEICDOYZVUTLN-UHFFFAOYSA-N 0.000 claims 1
- AFSOOPRQPFBEOM-UHFFFAOYSA-N n-[2-(4-aminophenyl)ethyl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound C1=CC(N)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(N)N=CC=2)S1 AFSOOPRQPFBEOM-UHFFFAOYSA-N 0.000 claims 1
- GMHIHHJFPKGLTE-UHFFFAOYSA-N n-[2-(4-bromophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(Br)=CC=2)=N1 GMHIHHJFPKGLTE-UHFFFAOYSA-N 0.000 claims 1
- SNEBFCVAIRGLGQ-UHFFFAOYSA-N n-[2-(4-chlorophenyl)-4-hydroxybutyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(CCO)C=2C=CC(Cl)=CC=2)=N1 SNEBFCVAIRGLGQ-UHFFFAOYSA-N 0.000 claims 1
- YPNATZHZOCDUHJ-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(Cl)=CC=2)=N1 YPNATZHZOCDUHJ-UHFFFAOYSA-N 0.000 claims 1
- GGRVIJWDDOHCBW-UHFFFAOYSA-N n-[2-(4-ethoxyphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound C1=CC(OCC)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC)N=CC=2)S1 GGRVIJWDDOHCBW-UHFFFAOYSA-N 0.000 claims 1
- ZFQUVFPIYPYCSV-UHFFFAOYSA-N n-[2-(4-ethylphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound C1=CC(CC)=CC=C1CCNC(=O)C1=CC=C(C=2N=C(NC)N=CC=2)S1 ZFQUVFPIYPYCSV-UHFFFAOYSA-N 0.000 claims 1
- JXRYCYBMVNQOMQ-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-sulfonamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)S(=O)(=O)NCCC=2C=CC(F)=CC=2)=N1 JXRYCYBMVNQOMQ-UHFFFAOYSA-N 0.000 claims 1
- FATJKXOPTHBIOJ-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-5-[6-(methylamino)pyridin-2-yl]thiophene-2-carboxamide Chemical compound CNC1=CC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(F)=CC=2)=N1 FATJKXOPTHBIOJ-UHFFFAOYSA-N 0.000 claims 1
- AAWNVQYZVTTYED-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-5-pyridin-4-ylthiophene-2-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C1=CC=C(C=2C=CN=CC=2)S1 AAWNVQYZVTTYED-UHFFFAOYSA-N 0.000 claims 1
- RJVLYJURXGSMMB-UHFFFAOYSA-N n-[2-(4-fluorophenyl)ethyl]-n-methyl-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)N(C)CCC=2C=CC(F)=CC=2)=N1 RJVLYJURXGSMMB-UHFFFAOYSA-N 0.000 claims 1
- ZZYCUCRSTVKYIG-UHFFFAOYSA-N n-[2-(4-methoxyphenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCC=2C=CC(OC)=CC=2)=N1 ZZYCUCRSTVKYIG-UHFFFAOYSA-N 0.000 claims 1
- NMHPRSZNSIRZJD-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCN(C)C)=N1 NMHPRSZNSIRZJD-UHFFFAOYSA-N 0.000 claims 1
- ATXIGCMNGRDMPV-UHFFFAOYSA-N n-[3-(4-fluorophenyl)propyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCCCC=2C=CC(F)=CC=2)=N1 ATXIGCMNGRDMPV-UHFFFAOYSA-N 0.000 claims 1
- HKAXPJOLHAZMSO-UHFFFAOYSA-N n-[3-amino-1-(4-chlorophenyl)propyl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C(CCN)NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 HKAXPJOLHAZMSO-UHFFFAOYSA-N 0.000 claims 1
- WMQIUPWPTGHQKW-UHFFFAOYSA-N n-[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C(=CC=CC=2)Cl)=N1 WMQIUPWPTGHQKW-UHFFFAOYSA-N 0.000 claims 1
- NDHYWODVGZGNOR-UHFFFAOYSA-N n-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=C(F)C(F)=CC=2)=N1 NDHYWODVGZGNOR-UHFFFAOYSA-N 0.000 claims 1
- HGCNQYOKNWGTKD-UHFFFAOYSA-N n-[4-(3-chlorophenyl)-1,3-thiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=C(Cl)C=CC=2)=N1 HGCNQYOKNWGTKD-UHFFFAOYSA-N 0.000 claims 1
- RAKLDOKJEVXJIG-UHFFFAOYSA-N n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC=C(N=2)C=2C=CC(OC)=CC=2)=N1 RAKLDOKJEVXJIG-UHFFFAOYSA-N 0.000 claims 1
- YKNUPOUJWCCICK-UHFFFAOYSA-N n-[4-(aminomethyl)-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound N=1C=2C(CN)=CC=CC=2SC=1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 YKNUPOUJWCCICK-UHFFFAOYSA-N 0.000 claims 1
- OVEZBCVYUORCFG-UHFFFAOYSA-N n-[4-(aminomethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC=CC(CN)=C3N=2)=N1 OVEZBCVYUORCFG-UHFFFAOYSA-N 0.000 claims 1
- SXVBGQYMFWTIMA-UHFFFAOYSA-N n-[4-amino-2-(4-chlorophenyl)butyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC(CCN)C=2C=CC(Cl)=CC=2)=N1 SXVBGQYMFWTIMA-UHFFFAOYSA-N 0.000 claims 1
- OFKNVJOYELBTFQ-UHFFFAOYSA-N n-[4-chloro-6-(2-nitroethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CC[N+]([O-])=O)=CC(Cl)=C3N=2)=N1 OFKNVJOYELBTFQ-UHFFFAOYSA-N 0.000 claims 1
- GUCFIBZUUWTNOO-UHFFFAOYSA-N n-[4-chloro-6-(morpholin-4-ylmethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN4CCOCC4)=CC(Cl)=C3N=2)=N1 GUCFIBZUUWTNOO-UHFFFAOYSA-N 0.000 claims 1
- ASZFEJKKBAQPRU-UHFFFAOYSA-N n-[4-chloro-6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(OC(F)(F)F)=CC(Cl)=C3N=2)=N1 ASZFEJKKBAQPRU-UHFFFAOYSA-N 0.000 claims 1
- CLKUZOMGQGYILX-UHFFFAOYSA-N n-[4-chloro-6-(trifluoromethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(=CC(Cl)=C3N=2)C(F)(F)F)=N1 CLKUZOMGQGYILX-UHFFFAOYSA-N 0.000 claims 1
- XRNOLADMONHKAM-UHFFFAOYSA-N n-[4-chloro-6-[(dimethylamino)methyl]-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN(C)C)=CC(Cl)=C3N=2)=N1 XRNOLADMONHKAM-UHFFFAOYSA-N 0.000 claims 1
- VYDHJJKKXAJQAO-UHFFFAOYSA-N n-[4-chloro-7-(hydroxymethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=C(CO)C=CC(Cl)=C3N=2)=N1 VYDHJJKKXAJQAO-UHFFFAOYSA-N 0.000 claims 1
- KGZPOPXFJLNAKS-UHFFFAOYSA-N n-[5-(3-bromo-4-methoxyphenyl)-1,3-thiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC(=CN=2)C=2C=C(Br)C(OC)=CC=2)=N1 KGZPOPXFJLNAKS-UHFFFAOYSA-N 0.000 claims 1
- QZSOJEQIMXJRLS-UHFFFAOYSA-N n-[6-(2-aminoethyl)-4-chloro-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CCN)=CC(Cl)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 QZSOJEQIMXJRLS-UHFFFAOYSA-N 0.000 claims 1
- WIECFCHPCPFVDC-UHFFFAOYSA-N n-[6-(2-aminoethyl)-4-chloro-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CCN)=CC(Cl)=C3N=2)=N1 WIECFCHPCPFVDC-UHFFFAOYSA-N 0.000 claims 1
- AOBXWRCCZHGOJW-UHFFFAOYSA-N n-[6-(aminomethyl)-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CN)=CC=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 AOBXWRCCZHGOJW-UHFFFAOYSA-N 0.000 claims 1
- LMKQBFNXPKGPAO-UHFFFAOYSA-N n-[6-(aminomethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN)=CC=C3N=2)=N1 LMKQBFNXPKGPAO-UHFFFAOYSA-N 0.000 claims 1
- KAUVTOXYGIWIGL-UHFFFAOYSA-N n-[6-(aminomethyl)-4-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CN)=CC(OC(F)(F)F)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 KAUVTOXYGIWIGL-UHFFFAOYSA-N 0.000 claims 1
- DJYKMVNRPVTKEK-UHFFFAOYSA-N n-[6-(aminomethyl)-4-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN)=CC(OC(F)(F)F)=C3N=2)=N1 DJYKMVNRPVTKEK-UHFFFAOYSA-N 0.000 claims 1
- FCHSTIRKQIBTHF-UHFFFAOYSA-N n-[6-(aminomethyl)-4-(trifluoromethyl)-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CN)=CC(C(F)(F)F)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 FCHSTIRKQIBTHF-UHFFFAOYSA-N 0.000 claims 1
- FPQORDSVXQXJLB-UHFFFAOYSA-N n-[6-(aminomethyl)-4-(trifluoromethyl)-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN)=CC(=C3N=2)C(F)(F)F)=N1 FPQORDSVXQXJLB-UHFFFAOYSA-N 0.000 claims 1
- YMXTUQYXYGVDSZ-UHFFFAOYSA-N n-[6-(aminomethyl)-4-bromo-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CN)=CC(Br)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 YMXTUQYXYGVDSZ-UHFFFAOYSA-N 0.000 claims 1
- NBKABANUFOYBEC-UHFFFAOYSA-N n-[6-(aminomethyl)-4-bromo-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN)=CC(Br)=C3N=2)=N1 NBKABANUFOYBEC-UHFFFAOYSA-N 0.000 claims 1
- IRUQMRLGGUBPCE-UHFFFAOYSA-N n-[6-(aminomethyl)-4-chloro-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CN)=CC(Cl)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 IRUQMRLGGUBPCE-UHFFFAOYSA-N 0.000 claims 1
- HBPCATNHBDQBIH-UHFFFAOYSA-N n-[6-(aminomethyl)-4-chloro-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN)=CC(Cl)=C3N=2)=N1 HBPCATNHBDQBIH-UHFFFAOYSA-N 0.000 claims 1
- NPBLUDZLSPNADJ-UHFFFAOYSA-N n-[6-(aminomethyl)-4-methyl-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=CC(CN)=CC(C)=C3N=2)=N1 NPBLUDZLSPNADJ-UHFFFAOYSA-N 0.000 claims 1
- OVDJAYFMPSBZRQ-UHFFFAOYSA-N n-[6-(aminomethyl)-8-chloroquinolin-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound C1=CC2=CC(CN)=CC(Cl)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 OVDJAYFMPSBZRQ-UHFFFAOYSA-N 0.000 claims 1
- NVOKDHJNTDQNMA-VIFPVBQESA-N n-[6-[[[(2s)-2-aminopropanoyl]amino]methyl]-4-chloro-1,3-benzothiazol-2-yl]-5-(2-aminopyrimidin-4-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(CNC(=O)[C@@H](N)C)=CC(Cl)=C2N=C1NC(=O)C(S1)=CC=C1C1=CC=NC(N)=N1 NVOKDHJNTDQNMA-VIFPVBQESA-N 0.000 claims 1
- OKZUMVGXJFQHGB-UHFFFAOYSA-N n-[7-(aminomethyl)-4-chloro-1,3-benzothiazol-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NC=2SC3=C(CN)C=CC(Cl)=C3N=2)=N1 OKZUMVGXJFQHGB-UHFFFAOYSA-N 0.000 claims 1
- KMOJYIAAOSYDMM-UHFFFAOYSA-N n-[[1-(4-chlorophenyl)cyclopropyl]methyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide Chemical compound CNC1=NC=CC(C=2SC(=CC=2)C(=O)NCC2(CC2)C=2C=CC(Cl)=CC=2)=N1 KMOJYIAAOSYDMM-UHFFFAOYSA-N 0.000 claims 1
- WRNZVLSGKACYLF-UHFFFAOYSA-N n-[[5-(2-aminopyrimidin-4-yl)thiophen-2-yl]methyl]-4-chloro-1,3-benzothiazol-2-amine Chemical compound NC1=NC=CC(C=2SC(CNC=3SC4=CC=CC(Cl)=C4N=3)=CC=2)=N1 WRNZVLSGKACYLF-UHFFFAOYSA-N 0.000 claims 1
- 229960005190 phenylalanine Drugs 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- VSCGRMUDBNQJNB-UHFFFAOYSA-N pyrimidin-2-ylcarbamic acid Chemical compound OC(=O)NC1=NC=CC=N1 VSCGRMUDBNQJNB-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 abstract description 8
- 206010039491 Sarcoma Diseases 0.000 abstract description 5
- 230000002062 proliferating effect Effects 0.000 abstract description 5
- 208000035269 cancer or benign tumor Diseases 0.000 abstract description 3
- 208000003200 Adenoma Diseases 0.000 abstract description 2
- 206010001233 Adenoma benign Diseases 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 122
- 239000000243 solution Substances 0.000 description 113
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 75
- 108091008611 Protein Kinase B Proteins 0.000 description 59
- 230000002829 reductive effect Effects 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 58
- 230000015572 biosynthetic process Effects 0.000 description 51
- 239000003039 volatile agent Substances 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 45
- 229910052938 sodium sulfate Inorganic materials 0.000 description 45
- 235000011152 sodium sulphate Nutrition 0.000 description 45
- 150000001408 amides Chemical class 0.000 description 37
- 239000012074 organic phase Substances 0.000 description 37
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 239000012267 brine Substances 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000000758 substrate Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 239000013058 crude material Substances 0.000 description 28
- 238000000746 purification Methods 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 24
- 150000001412 amines Chemical class 0.000 description 23
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- 239000000725 suspension Substances 0.000 description 21
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 20
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000004007 reversed phase HPLC Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 150000001345 alkine derivatives Chemical class 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000009833 condensation Methods 0.000 description 10
- 230000005494 condensation Effects 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 0 CC=*C(C(*)=C(*P)*C*1)=C1C1CCCCC1 Chemical compound CC=*C(C(*)=C(*P)*C*1)=C1C1CCCCC1 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 8
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 8
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 101150051155 Akt3 gene Proteins 0.000 description 7
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 7
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 7
- 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 7
- 102100025198 Protein DBF4 homolog A Human genes 0.000 description 7
- 150000005005 aminopyrimidines Chemical class 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 238000007127 saponification reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- VJQCNCOGZPSOQZ-UHFFFAOYSA-N 1-Methylguanidine hydrochloride Chemical compound [Cl-].C[NH2+]C(N)=N VJQCNCOGZPSOQZ-UHFFFAOYSA-N 0.000 description 6
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 6
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000014429 Insulin-like growth factor Human genes 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 229940095074 cyclic amp Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000003828 vacuum filtration Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000005368 heteroarylthio group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- VHJKDOLGYMULOP-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1Cl VHJKDOLGYMULOP-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 125000005110 aryl thio group Chemical group 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 125000005366 cycloalkylthio group Chemical group 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009957 hemming Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 3
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 101150073900 PTEN gene Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 3
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000031709 bromination Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- VQXINLNPICQTLR-UHFFFAOYSA-N carbonyl diazide Chemical compound [N-]=[N+]=NC(=O)N=[N+]=[N-] VQXINLNPICQTLR-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 238000003271 compound fluorescence assay Methods 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 208000007750 pseudohypoaldosteronism Diseases 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 230000021595 spermatogenesis Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- BZZXQZOBAUXLHZ-UHFFFAOYSA-N (c-methylsulfanylcarbonimidoyl)azanium;sulfate Chemical compound CSC(N)=N.CSC(N)=N.OS(O)(=O)=O BZZXQZOBAUXLHZ-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- POEQDLUGPJFPAH-UHFFFAOYSA-N 4-(5-aminothiophen-2-yl)pyrimidin-2-amine Chemical group S1C(N)=CC=C1C1=CC=NC(N)=N1 POEQDLUGPJFPAH-UHFFFAOYSA-N 0.000 description 2
- LKFMAVHEOCJUAO-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)thiophene-2-sulfonamide Chemical compound NC1=NC=CC(C=2SC(=CC=2)S(N)(=O)=O)=N1 LKFMAVHEOCJUAO-UHFFFAOYSA-N 0.000 description 2
- ITJYEAPIPRFTNT-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)thiophene-3-carboxamide Chemical compound NC(=O)C1=CSC(C=2N=C(N)N=CC=2)=C1 ITJYEAPIPRFTNT-UHFFFAOYSA-N 0.000 description 2
- 150000000565 5-membered heterocyclic compounds Chemical class 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 2
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000003794 Mini-chromosome maintenance proteins Human genes 0.000 description 2
- 108090000159 Mini-chromosome maintenance proteins Proteins 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000009421 Myristica fragrans Nutrition 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 2
- 238000006411 Negishi coupling reaction Methods 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005012 alkyl thioether group Chemical group 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000004637 cellular stress Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000001726 chromosome structure Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000001115 mace Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VBMWKMUTTTVHTM-UHFFFAOYSA-N n-(1h-imidazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC=CN1 VBMWKMUTTTVHTM-UHFFFAOYSA-N 0.000 description 2
- YUFDOPVABDSMTF-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-3-carboxamide Chemical compound CNC1=NC=CC(C=2SC=C(C=2)C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)=N1 YUFDOPVABDSMTF-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000006726 (C1-C5) alkenyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 description 1
- WYRRTJKOMZONQO-UHFFFAOYSA-N 1,3-benzothiazole-6-carbonitrile Chemical compound N#CC1=CC=C2N=CSC2=C1 WYRRTJKOMZONQO-UHFFFAOYSA-N 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- HXVLWNKFMNRJED-UHFFFAOYSA-N 1-(4-bromothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC(Br)=CS1 HXVLWNKFMNRJED-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- VQSJAWPFQCXIOB-VODLGYORSA-N 2,3-dihydroxypropyl [(1r,2r,3s,4r,5r,6s)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl] hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O VQSJAWPFQCXIOB-VODLGYORSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- IXSCGBODJGIJNN-UHFFFAOYSA-N 2-(4-fluorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(F)C=C1 IXSCGBODJGIJNN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QWYCICFIQQOYLG-UHFFFAOYSA-N 2-amino-4-chloro-1,3-benzothiazole-6-carbonitrile Chemical compound C1=C(C#N)C=C2SC(N)=NC2=C1Cl QWYCICFIQQOYLG-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- OYBFKJFWVAZRMI-UHFFFAOYSA-N 2-bromo-4-chloro-1,3-benzothiazole Chemical group ClC1=CC=CC2=C1N=C(Br)S2 OYBFKJFWVAZRMI-UHFFFAOYSA-N 0.000 description 1
- KJKIPRQNFDUULB-UHFFFAOYSA-N 2-chloro-4-iodopyridine Chemical compound ClC1=CC(I)=CC=N1 KJKIPRQNFDUULB-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical compound CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- CCZWSTFVHJPCEM-UHFFFAOYSA-N 2-iodopyridine Chemical compound IC1=CC=CC=N1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- OKEHURCMYKPVFW-UHFFFAOYSA-N 2-methoxythiophene Chemical compound COC1=CC=CS1 OKEHURCMYKPVFW-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 1
- YADOEPHJIBKBCN-UHFFFAOYSA-N 3-chloro-2-nitroaniline Chemical compound NC1=CC=CC(Cl)=C1[N+]([O-])=O YADOEPHJIBKBCN-UHFFFAOYSA-N 0.000 description 1
- ATKZUBXBEFBHPD-UHFFFAOYSA-N 3-chloro-2h-1,3-benzothiazol-4-amine Chemical compound NC1=CC=CC2=C1N(Cl)CS2 ATKZUBXBEFBHPD-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- CBKDCOKSXCTDAA-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1-benzothiophene Chemical compound C1CCCC2=C1C=CS2 CBKDCOKSXCTDAA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- OEQQFQXMCPMEIH-UHFFFAOYSA-N 4-chloro-1,3-benzothiazol-2-amine Chemical compound C1=CC=C2SC(N)=NC2=C1Cl OEQQFQXMCPMEIH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- YEBCRAVYUWNFQT-UHFFFAOYSA-N 4-methoxy-1,3-benzothiazol-2-amine Chemical compound COC1=CC=CC2=C1N=C(N)S2 YEBCRAVYUWNFQT-UHFFFAOYSA-N 0.000 description 1
- RAJCUGZJBWJAPL-UHFFFAOYSA-N 4-thiophen-2-ylpyridin-2-amine Chemical group C1=NC(N)=CC(C=2SC=CC=2)=C1 RAJCUGZJBWJAPL-UHFFFAOYSA-N 0.000 description 1
- KHTGYJRTNNIIBM-UHFFFAOYSA-N 4-thiophen-2-ylpyridine Chemical compound C1=CSC(C=2C=CN=CC=2)=C1 KHTGYJRTNNIIBM-UHFFFAOYSA-N 0.000 description 1
- IXOUSLAWDHODKH-UHFFFAOYSA-N 4-thiophen-2-ylpyrimidin-2-amine Chemical class NC1=NC=CC(C=2SC=CC=2)=N1 IXOUSLAWDHODKH-UHFFFAOYSA-N 0.000 description 1
- BWFAPQRLXWNZLX-UHFFFAOYSA-N 4-thiophen-2-ylpyrimidine Chemical compound C1=CSC(C=2N=CN=CC=2)=C1 BWFAPQRLXWNZLX-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- WUSSJIDQVJHIMA-UHFFFAOYSA-N 5-(2-aminopyridin-4-yl)thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC=C1C1=CC=NC(N)=C1 WUSSJIDQVJHIMA-UHFFFAOYSA-N 0.000 description 1
- OQGIKNPOYTVNNF-UHFFFAOYSA-N 5-boronothiophene-2-carboxylic acid Chemical compound OB(O)C1=CC=C(C(O)=O)S1 OQGIKNPOYTVNNF-UHFFFAOYSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 102000004120 Annexin A3 Human genes 0.000 description 1
- 108090000670 Annexin A3 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 229910014265 BrCl Inorganic materials 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- LIKIMWYKJUFVJP-UHFFFAOYSA-N CC(c1ccc(C(O)=O)[s]1)=O Chemical compound CC(c1ccc(C(O)=O)[s]1)=O LIKIMWYKJUFVJP-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 101710105094 Cyclic AMP-responsive element-binding protein Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 206010037113 Pseudoaldosteronism Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 101710177717 Terminase small subunit Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- XIXIZXAQBWOEFW-UHFFFAOYSA-N [2-amino-3-(2,4-dichlorophenyl)propyl]-diazonioazanide Chemical compound [N-]=[N+]=NCC(N)CC1=CC=C(Cl)C=C1Cl XIXIZXAQBWOEFW-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000007929 acylimidazolides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000008848 allosteric regulation Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 150000004652 butanoic acids Chemical class 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 102000028861 calmodulin binding Human genes 0.000 description 1
- 108091000084 calmodulin binding Proteins 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000010319 checkpoint response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- QVQGTNFYPJQJNM-UHFFFAOYSA-N dicyclohexylmethanamine Chemical compound C1CCCCC1C(N)C1CCCCC1 QVQGTNFYPJQJNM-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PDIKYTHWLCYLEG-UHFFFAOYSA-N ethyl 5-acetylthiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C(C)=O)S1 PDIKYTHWLCYLEG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- PQPVPZTVJLXQAS-UHFFFAOYSA-N hydroxy-methyl-phenylsilicon Chemical class C[Si](O)C1=CC=CC=C1 PQPVPZTVJLXQAS-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- MSXIOWULDXZJLX-UHFFFAOYSA-N n,n-dimethylpyrimidin-4-amine Chemical compound CN(C)C1=CC=NC=N1 MSXIOWULDXZJLX-UHFFFAOYSA-N 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- NGGXACLSAZXJGM-UHFFFAOYSA-N n-(diaminomethylidene)acetamide Chemical compound CC(=O)N=C(N)N NGGXACLSAZXJGM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 1
- 150000003913 phosphatidylinositol 3,4-bisphosphates Chemical class 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical compound NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-N sodium;2-[dodecanoyl(methyl)amino]acetic acid Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC(O)=O KSAVQLQVUXSOCR-UHFFFAOYSA-N 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- CSABAZBYIWDIDE-UHFFFAOYSA-N sulfino hydrogen sulfite Chemical class OS(=O)OS(O)=O CSABAZBYIWDIDE-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- HIFKYVZCIZCINB-UHFFFAOYSA-N tert-butyl 2-(aminomethyl)-2h-1,3-benzothiazole-3-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C(CN)SC2=C1 HIFKYVZCIZCINB-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 108091011140 tropomyosin binding proteins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- LQUPKVMEAATBSL-UHFFFAOYSA-L zinc;2,3,4-trichlorophenolate Chemical compound [Zn+2].[O-]C1=CC=C(Cl)C(Cl)=C1Cl.[O-]C1=CC=C(Cl)C(Cl)=C1Cl LQUPKVMEAATBSL-UHFFFAOYSA-L 0.000 description 1
- DZNBTCXRFDXCFM-UHFFFAOYSA-M zinc;2-(2h-thiophen-2-id-5-yl)-1,3-dioxolane;bromide Chemical compound Br[Zn+].O1CCOC1C1=CC=[C-]S1 DZNBTCXRFDXCFM-UHFFFAOYSA-M 0.000 description 1
- YFPILNMHJDQSAK-UHFFFAOYSA-M zinc;ethyl 2h-thiophen-2-ide-5-carboxylate;bromide Chemical compound Br[Zn+].CCOC(=O)C1=CC=[C-]S1 YFPILNMHJDQSAK-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55834204P | 2004-03-30 | 2004-03-30 | |
| PCT/US2005/010690 WO2005095386A1 (en) | 2004-03-30 | 2005-03-30 | Substituted thiophene derivatives as anti-cancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007531757A true JP2007531757A (ja) | 2007-11-08 |
| JP2007531757A5 JP2007531757A5 (https=) | 2008-04-17 |
Family
ID=34972501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506511A Pending JP2007531757A (ja) | 2004-03-30 | 2005-03-30 | 抗癌剤としての置換チオフェン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7470701B2 (https=) |
| EP (1) | EP1732919A1 (https=) |
| JP (1) | JP2007531757A (https=) |
| CN (1) | CN1989131A (https=) |
| AU (1) | AU2005228899A1 (https=) |
| BR (1) | BRPI0508230A (https=) |
| CA (1) | CA2561977A1 (https=) |
| IL (1) | IL177799A0 (https=) |
| MX (1) | MXPA06010520A (https=) |
| RU (1) | RU2006138036A (https=) |
| WO (1) | WO2005095386A1 (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518866A (ja) * | 2008-04-30 | 2011-06-30 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 5−(2−アミノ−ピリミジン−4−イル)−2−アリール−lH−ピロール−3−カルボキサミドの製造方法 |
| WO2013161871A1 (ja) * | 2012-04-25 | 2013-10-31 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
| JP5689454B2 (ja) * | 2010-02-17 | 2015-03-25 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2016517878A (ja) * | 2013-04-30 | 2016-06-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited | Zesteホモログ2エンハンサー阻害剤 |
| JP2018531225A (ja) * | 2015-09-18 | 2018-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Irak阻害剤としてのヘテロアリール化合物及びその使用 |
| JP2018535270A (ja) * | 2015-12-07 | 2018-11-29 | 蘇州信諾維医薬科技有限公司Suzhou Sinovent Pharmaceuticals Co., Ltd. | 5員複素環式アミド系wnt経路阻害剤 |
| JP2019504900A (ja) * | 2016-02-16 | 2019-02-21 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物 |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| CN101624391A (zh) * | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| US7402608B2 (en) * | 2002-12-10 | 2008-07-22 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US20080293716A1 (en) * | 2004-01-30 | 2008-11-27 | Smithkline Beecham Corporation | Chemical Compounds |
| EP1907385A4 (en) * | 2005-07-26 | 2009-05-06 | Smithkline Beecham Corp | LINKS |
| WO2007016292A2 (en) * | 2005-07-27 | 2007-02-08 | Vertex Pharmaceuticals Incorporated | Heterocyclic amides as biofilm modulators |
| US7803806B2 (en) | 2005-11-03 | 2010-09-28 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
| MY149143A (en) * | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| AU2007208358A1 (en) | 2006-01-23 | 2007-08-02 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| ZA200808966B (en) * | 2006-03-27 | 2010-03-31 | Nerviano Medical Sciences Srl | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
| EP2418210A1 (en) * | 2006-04-13 | 2012-02-15 | Vertex Pharmceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| AU2007268056A1 (en) | 2006-05-23 | 2007-12-06 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| JP2009538309A (ja) | 2006-05-23 | 2009-11-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド |
| CA2670260A1 (en) | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| AU2012233017B2 (en) * | 2007-02-07 | 2013-01-10 | Novartis Ag | Inhibitors of Akt activity |
| WO2008098105A1 (en) * | 2007-02-07 | 2008-08-14 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
| AU2008276512A1 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| RS54303B1 (sr) | 2007-07-19 | 2016-02-29 | Lundbeck, H., A/S | 5-člani heterociklični amidi i srodna jedinjenja |
| PL2201012T3 (pl) * | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
| JP2011525930A (ja) * | 2008-06-26 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Akt活性の阻害剤 |
| EP2303852A4 (en) * | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | ACTIVITY INHIBITORS AKT |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US20110288142A1 (en) | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| EP2403857B1 (en) | 2009-03-05 | 2013-12-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
| WO2011011303A1 (en) | 2009-07-21 | 2011-01-27 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| ES2559437T3 (es) | 2009-09-09 | 2016-02-12 | Gilead Sciences, Inc. | Inhibidores de virus de la familia Flaviviridae |
| AP3576A (en) | 2010-01-15 | 2016-02-08 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| CA2785563C (en) | 2010-01-15 | 2019-05-14 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2013001660A (es) | 2010-08-11 | 2013-06-03 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TW201307309A (zh) | 2010-10-13 | 2013-02-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| AU2012280959B2 (en) | 2011-07-13 | 2015-08-06 | Gilead Sciences, Inc. | Thiophen-2-carboxylic acid derivatives useful as inhibitors of Flaviviridae viruses |
| TWI490221B (zh) * | 2011-08-15 | 2015-07-01 | Takeda Pharmaceutical | 雜環化合物 |
| PT3184523T (pt) * | 2012-04-13 | 2019-09-26 | Eisai R&D Man Co Ltd | Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico |
| US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| CN104262289B (zh) * | 2014-10-09 | 2016-06-08 | 武汉大学 | 一种苯并噻唑衍生物及其抗肿瘤用途 |
| LT3319959T (lt) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017063966A1 (en) * | 2015-10-13 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds |
| RS62959B1 (sr) | 2017-01-11 | 2022-03-31 | Alkermes Inc | Biciklični inhibitori histon-deacetilaze |
| GB201712567D0 (en) | 2017-08-04 | 2017-09-20 | Karin & Sten Mortstedt Cbd Solutions Ab | Selective ligands for tau aggregates |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| CN109400595B (zh) * | 2018-12-24 | 2020-07-17 | 深圳市第二人民医院 | 一类含噻吩环的抗癌化合物 |
| CA3131930A1 (en) * | 2019-02-28 | 2020-09-03 | Kezar Life Sciences | Thiazole derivatives as protein secretion inhibitors |
| US20220389026A1 (en) * | 2019-08-20 | 2022-12-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tetracyclic compound used as cdc7 inhibitor |
| CN115536648B (zh) * | 2021-06-29 | 2024-09-17 | 深圳开悦生命科技有限公司 | 一类抑制rna解旋酶dhx33的多环化合物及其应用 |
| CN114644582B (zh) * | 2022-04-11 | 2024-03-29 | 中原工学院 | 一种苯基双硫脲类化合物的制备方法 |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500532A (ja) * | 1997-06-27 | 2001-01-16 | ローヌ―プーラン ローラー ファーマシューティカルズ インコーポレイテッド | 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド |
| DE10034623A1 (de) * | 2000-07-17 | 2002-01-31 | Bayer Ag | Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren |
| JP2002037784A (ja) * | 2000-05-17 | 2002-02-06 | Nikken Chem Co Ltd | 新規チオフェンアミド化合物 |
| JP2002521408A (ja) * | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| WO2002083667A2 (en) * | 2001-04-13 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2003004472A1 (en) * | 2001-07-05 | 2003-01-16 | Astrazeneca Ab | Arylamines for the treatment of conditions associated with gsk-3 |
| WO2003008405A1 (fr) * | 2001-07-18 | 2003-01-30 | L'oreal | Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques |
| WO2003037886A2 (en) * | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| WO2003086279A2 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003092686A1 (en) * | 2002-04-27 | 2003-11-13 | Astrazeneca Ab | Inhibitors of histone deacetylase |
| WO2003101985A1 (en) * | 2002-05-29 | 2003-12-11 | Amgen Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| WO2004005278A1 (en) * | 2002-07-05 | 2004-01-15 | Cyclacel Limited | Bisarylsulfonamide compounds and their use in cancer therapy |
| WO2004013130A1 (en) * | 2002-08-02 | 2004-02-12 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| WO2004041813A1 (en) * | 2002-10-30 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| WO2004089913A1 (en) * | 2003-04-11 | 2004-10-21 | Novartis Ag | Aminopyrimidine derivatives and their medical use |
| JP2007519753A (ja) * | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3908012A (en) * | 1970-10-05 | 1975-09-23 | Pfizer | Arylpyrimidines-inhibitors of platelet aggregation and bronchodilators |
| US6034093A (en) * | 1995-06-07 | 2000-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| US5731315A (en) * | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| WO2000075129A1 (en) | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| JP4064671B2 (ja) | 2000-02-25 | 2008-03-19 | エフ.ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
-
2005
- 2005-03-30 MX MXPA06010520A patent/MXPA06010520A/es active IP Right Grant
- 2005-03-30 AU AU2005228899A patent/AU2005228899A1/en not_active Abandoned
- 2005-03-30 BR BRPI0508230-7A patent/BRPI0508230A/pt not_active IP Right Cessation
- 2005-03-30 US US11/095,993 patent/US7470701B2/en not_active Expired - Fee Related
- 2005-03-30 RU RU2006138036/04A patent/RU2006138036A/ru not_active Application Discontinuation
- 2005-03-30 EP EP05760186A patent/EP1732919A1/en not_active Withdrawn
- 2005-03-30 JP JP2007506511A patent/JP2007531757A/ja active Pending
- 2005-03-30 CA CA002561977A patent/CA2561977A1/en not_active Abandoned
- 2005-03-30 WO PCT/US2005/010690 patent/WO2005095386A1/en not_active Ceased
- 2005-03-30 CN CNA2005800105750A patent/CN1989131A/zh active Pending
-
2006
- 2006-08-31 IL IL177799A patent/IL177799A0/en unknown
-
2008
- 2008-05-29 US US12/129,367 patent/US20080255120A1/en not_active Abandoned
Patent Citations (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500532A (ja) * | 1997-06-27 | 2001-01-16 | ローヌ―プーラン ローラー ファーマシューティカルズ インコーポレイテッド | 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド |
| JP2002521408A (ja) * | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
| JP2002037784A (ja) * | 2000-05-17 | 2002-02-06 | Nikken Chem Co Ltd | 新規チオフェンアミド化合物 |
| DE10034623A1 (de) * | 2000-07-17 | 2002-01-31 | Bayer Ag | Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren |
| WO2002083667A2 (en) * | 2001-04-13 | 2002-10-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2003004472A1 (en) * | 2001-07-05 | 2003-01-16 | Astrazeneca Ab | Arylamines for the treatment of conditions associated with gsk-3 |
| WO2003008405A1 (fr) * | 2001-07-18 | 2003-01-30 | L'oreal | Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques |
| WO2003037886A2 (en) * | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| WO2003086279A2 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003092686A1 (en) * | 2002-04-27 | 2003-11-13 | Astrazeneca Ab | Inhibitors of histone deacetylase |
| WO2003101985A1 (en) * | 2002-05-29 | 2003-12-11 | Amgen Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| WO2004005278A1 (en) * | 2002-07-05 | 2004-01-15 | Cyclacel Limited | Bisarylsulfonamide compounds and their use in cancer therapy |
| WO2004013130A1 (en) * | 2002-08-02 | 2004-02-12 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| WO2004041813A1 (en) * | 2002-10-30 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| JP2006514684A (ja) * | 2002-10-30 | 2006-05-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Rockおよび他のプロテインキナーゼとして有用な組成物 |
| WO2004089913A1 (en) * | 2003-04-11 | 2004-10-21 | Novartis Ag | Aminopyrimidine derivatives and their medical use |
| JP2006522768A (ja) * | 2003-04-11 | 2006-10-05 | ノバルティス アクチエンゲゼルシャフト | アミノピリミジン誘導体およびそれらの医学的使用 |
| JP2007519753A (ja) * | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011518866A (ja) * | 2008-04-30 | 2011-06-30 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 5−(2−アミノ−ピリミジン−4−イル)−2−アリール−lH−ピロール−3−カルボキサミドの製造方法 |
| JP5689454B2 (ja) * | 2010-02-17 | 2015-03-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2013161871A1 (ja) * | 2012-04-25 | 2013-10-31 | 興和株式会社 | Tlr阻害作用を有するチオフェン誘導体 |
| JP2016517878A (ja) * | 2013-04-30 | 2016-06-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited | Zesteホモログ2エンハンサー阻害剤 |
| JP2018531225A (ja) * | 2015-09-18 | 2018-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Irak阻害剤としてのヘテロアリール化合物及びその使用 |
| JP7083750B2 (ja) | 2015-09-18 | 2022-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Irak阻害剤としてのヘテロアリール化合物及びその使用 |
| JP2018535270A (ja) * | 2015-12-07 | 2018-11-29 | 蘇州信諾維医薬科技有限公司Suzhou Sinovent Pharmaceuticals Co., Ltd. | 5員複素環式アミド系wnt経路阻害剤 |
| JP2019504900A (ja) * | 2016-02-16 | 2019-02-21 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | プロテインキナーゼ阻害剤である新規な2,3,5−置換チオフェン化合物 |
| US10442796B2 (en) | 2016-02-16 | 2019-10-15 | Korea Institute Of Science And Technology | 2,3,5-substituted thiophene compound as protein kinase inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2561977A1 (en) | 2005-10-13 |
| US20050256121A1 (en) | 2005-11-17 |
| WO2005095386A1 (en) | 2005-10-13 |
| US7470701B2 (en) | 2008-12-30 |
| IL177799A0 (en) | 2006-12-31 |
| BRPI0508230A (pt) | 2007-07-17 |
| MXPA06010520A (es) | 2007-03-26 |
| CN1989131A (zh) | 2007-06-27 |
| RU2006138036A (ru) | 2008-05-10 |
| US20080255120A1 (en) | 2008-10-16 |
| AU2005228899A1 (en) | 2005-10-13 |
| EP1732919A1 (en) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007531757A (ja) | 抗癌剤としての置換チオフェン誘導体 | |
| US7560467B2 (en) | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | |
| EP2493862B1 (en) | Imidazole derivatives as ido inhibitors | |
| CN101379060B (zh) | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 | |
| US8183240B2 (en) | Heteroaryls and uses thereof | |
| RU2559895C2 (ru) | Азотосодержащие производные гетероарилов | |
| US20100331315A1 (en) | Rhodanines and related heterocycles as kinase inhibitors | |
| US8124649B2 (en) | Oxindole compounds | |
| US7176314B2 (en) | Inflammation modulators | |
| US20080293716A1 (en) | Chemical Compounds | |
| KR20170027822A (ko) | 리신 특이적 데메틸라제-1의 저해제 | |
| US8796314B2 (en) | Heteroaryls and uses thereof | |
| HK1168106B (en) | Imidazole derivatives as ido inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080227 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110113 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110928 |